|
Indications:
Melanoma
Nivolumab as monotherapy or in combination with ipilimumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults.
Relative to nivolumab monotherapy, an increase in progression-free survival (PFS) for the combination of nivolumab with ipilimumab is established only in patients with low tumour PD-L1 expression (see sections 4.4 and 5.1).
Non-Small Cell Lung Cancer (NSCLC)
Nivolumab as monotherapy is indicated for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy in adults.
Renal Cell Carcinoma (RCC)
Nivolumab as monotherapy is indicated for the treatment of advanced renal cell carcinoma after prior therapy in adults.
Classical Hodgkin Lymphoma (cHL)
Nivolumab as monotherapy is indicated for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma (cHL) after autologous stem cell transplant (ASCT) and treatment with brentuximab vedotin (see section 5.1).
Squamous Cell Cancer of the Head and Neck (SCCHN)
Nivolumab as monotherapy is indicated for the treatment of recurrent or metastatic squamous cell cancer of the head and neck in adults progressing on or after platinum-based therapy (see section 5.1).
|